An observational study in Chronic Lymphocytic Leukemia, sponsored by AstraZeneca. Active, not recruiting at 34 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by AstraZeneca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca — 6 open to participants now, 21 under way, 5 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · AstraZeneca.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one has the largest planned enrollment of the 12 observational ones that give a count, is one of 6 that started in 2021, is one of 12 observational ones, reaches primary completion later than 11 of the 20 other live ones, and was the 31st registered.
2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →6 of the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
AstraZeneca · Sites in Belarus
Ages 18+
AstraZeneca · Sites in France
AstraZeneca · Sites in United States, Australia, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Canada and 7 more countries
Ages 18+
By country, each count listing its studies:
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,000 is above the median of 148 across 216 observational studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 103 across the 29 interventional studies, 136 across the 12 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
5 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT06548152AstraZenecaAQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database | 2026-12-31 |
| NCT05140369AstraZenecaCLL Therapy Approaches in Russia | 2027-03-31 |
| NCT06205498AstraZenecaAcalabrutinib Real World Italian obSErvational Study -ARISE | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is going to be a non-interventional study (NIS). Assessment of variables will be carried out using data on patient's treatment in real-life clinical setting. Patients should be enrolled into study after evaluation of eligibility criteria by the investigator. No additional procedures besides those already used in the routine clinical practice will be applied to the patients. Treatment assignment will be done according to the current practice.
Evaluation of efficacy and safety of any approaches used for CLL/SLL treatment is not the primary objective of this study, though there is no treatment of interest. Study procedures will comply with all the local regulatory requirements regarding AE reporting (pharmacovigilance).
It is planned to enroll approximately 6000 patients (suggested number of patients on WW\~1000 pts, 1L\~2750 pts, RR\~2250 pts)
During the course of study's prospective part, it is planned to carry out at approximately 5 visits:
(if unscheduled visit performed - the information should be filled on nearest visit).
It is expected to recruit approximately 6000 patients with CLL/SLL regardless of treatment stage and line.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sex
Time frame: Baseline
Date of diagnosis for CLL/SLL
Time frame: Baseline
Comorbidities
Time frame: Up to 2 years
ECOG status (0-1/≥2)
Time frame: Up to 2 years
Rai staging (0-IV)
Time frame: Up to 2 years
Cytogenetic tests
* TP53 gene mutation status * IGHV gene mutation status * complex karyotype * del13q status
Time frame: Up to 2 years
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Started Oct 2021 (actual). Primary completion is estimated for Mar 2027, 65 months after the start.
Of 34 industry-sponsored observational studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 66. This study's planned 65 months is above that.
Counting every sponsor, half of 104 studies reached it within 60 months; a quarter within 31 and three quarters within 176.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Lymphocytic, Chronic, B-Cell →